The active ingredient Tiotropium has been proven to be effective in treating COPD (Chronic Obstructive Pulmonary Disease) by improving the patient's quality of life through Zonda Inhaler technology which is easy to use and efficient.

Jakarta, 28 May 2024 – Actavis Indonesia, today introduced tiotropium products with ZONDA® inhaler technology in Indonesia. In collaboration with the Indonesian Lung Doctors Association (PDPI), Actavis Indonesia held a scientific seminar with the theme "Inhaler Technology and Drug Delivery Systems for Controlling Lung Disease", on Thursday, 23 May 2024 at the Aryaduta Hotel Menteng, Jakarta.

Data from the World Health Organization (WHO) states that chronic obstructive pulmonary disease (COPD) is the third cause of death worldwide, with a death rate of 3.23 million people suffering from COPD in 2019. [Source: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease (copd)]. COPD is a non-communicable disease that is a public health problem in Indonesia, the causal factors include high exposure to risk factors, such as host factors which are thought to be related to the incidence of COPD, including the increase in smoking in young age groups, and air pollution inside and outside outdoors or at work, as well as increasing life expectancy.

In his presentation, Dr. Dr. Susanthy. Djajalaksana, Sp.P(K) said, "COPD is a common disease, can be prevented and treated. The role of medical personnel in providing appropriate and early diagnoses is important, so as to reduce the progression of the disease and the risk of worse conditions or complications in COPD sufferers. In addition, ongoing care and monitoring is also very important to manage symptoms and prevent complications."

"With proper management of COPD, the quality of life for COPD sufferers will be better. The presence of tiotropium products with ZONDA® inhaler technology is expected to enrich the repertoire of COPD treatments in Indonesia," added Dr. Santhy.

Chronic obstructive pulmonary disease (COPD) is a disease that disrupts the respiratory system, where the lungs become inflamed over a long period of time. This inflammatory condition is clinically found in part of the lung organ or even all of it. This chronic pulmonary obstruction disease is progressive or can get worse over time. However, with proper treatment, people with chronic obstructive disease can be free from symptoms and have a better quality of life.

The use of inhalers containing tiotropium bromide is a medical method for controlling and preventing symptoms that arise due to asthma and COPD. Tiotropium is able to control symptoms, works by relaxing and widening the muscles in the respiratory tract so that COPD sufferers can breathe more easily.

Dr. Budhi Antariksa, Ph.D, Sp.P(K), who was the second speaker in this scientific seminar, explained, "Tiotropium is a useful treatment option for patients with chronic respiratory conditions, it has been clinically proven to be able to improve lung function, reduce shortness of breath, as well as acute respiratory problems. Administration of this drug can improve the quality of life of COPD patients."

In closing, Dr. Budhi also appealed to the medical community to advise COPD sufferers to avoid exposures, such as air pollution or cigarette smoke, which can make their respiratory tract worse.

Apart from providing exposure related to COPD, controlling and preventing symptoms, this seminar also introduced tiotropium with ZONDA® inhaler technology from Actavis Indonesia. Tiotropium has become the primary standard in the treatment of obstructive pulmonary disease and asthma. Tiotropium's active role is in opening respiratory obstructions through relaxing the respiratory tract muscles, so that air can enter and leave the lungs without obstacles. The use of ZONDA inhaler technology ensures measurable tiotropium levels and is effective in controlling the opening of the respiratory tract. The use of Tiotropium with Zonda technology must of course still be under the supervision of a doctor or expert.

Based on the experience of using tiotropium in COPD patients, regular use of this drug has been proven to not only help sufferers when they experience shortness of breath, but can also minimize the effects of the disease in daily life, so that sufferers can continue their activities and improve their quality of life without the risk of side effects. lower.

“COPD is included in the category of chronic diseases that cannot be cured, but with proper treatment patients can manage symptoms and slow the progress of the disease. "We are very proud to be able to hold a hybrid seminar with PDPI which aims to provide the latest information regarding the treatment system and management of lung disease," said Mr. Hanadi Setiarto as President Director of PT Actavis Indonesia.

"We also hope that the presence of tiotropium with ZONDA® inhaler from Actavis can be an option for COPD maintenance treatment in Indonesia. Regular use of tiotropium can help sufferers when they are short of breath, as well as minimizing the effects of disease in daily life, so that sufferers can continue to carry out activities and improve their quality of life, because it's not just about tiotropium, it's about living in premium." added Mr Hanadi.

Actavis presents Tiotropium with ZONDA® inhaler technology that is easy to carry and practical for patients who experience chronic respiratory problems. Tiotropium with ZONDA® inhaler technology on May 23 2024 is officially available on the Indonesian market, to get this medicine consumers can consult a doctor.